Medicus Pharma (NASDAQ:MDCX) Stock Moved Down to Strong Sell by Wall Street Zen

Wall Street Zen downgraded shares of Medicus Pharma (NASDAQ:MDCX) to a strong sell rating in a report published on Saturday morning,Wall Street Zen reports.

A number of other analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a research note on Friday, October 2nd. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $450.00.

Medicus Pharma Trading Down 5.2%

MDCX stock opened at $3.25 on Friday. The company has a market capitalization of $4.09 million, a PE ratio of -0.03 and a beta of 0.30. Medicus Pharma has a 12-month low of $2.92 and a 12-month high of $139.00. The business’s fifty day moving average price is $9.65 and its 200 day moving average price is $15.08.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Wednesday, August 12th. The company reported ($10.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.38) by ($4.12). Research analysts predict that Medicus Pharma will post -36.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Medicus Pharma

A hedge fund recently raised its stake in Medicus Pharma stock. Private Advisor Group LLC lifted its stake in shares of Medicus Pharma Ltd (NASDAQ:MDCX) by 36.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 240,055 shares of the company’s stock after acquiring an additional 64,560 shares during the quarter. Private Advisor Group LLC owned 0.61% of Medicus Pharma worth $110,000 as of its most recent filing with the Securities and Exchange Commission.

Medicus Pharma Company Profile

Medicus Pharma Ltd. is a life sciences company focused on acquiring, developing and commercializing innovative therapeutic and medical device technologies. Its activities are centered primarily on wound care, dermatology and related areas of medical treatment.

The company’s portfolio includes Natrox® Oxygen Wound Therapy, a device designed to deliver continuous topical oxygen to the wound site. The technology is intended to support the treatment of chronic and hard-to-heal wounds and may be used in clinical and home-care settings, subject to applicable regulatory approvals.

Medicus Pharma serves healthcare markets through the commercialization of its technologies and partnerships with medical professionals and distribution networks.